Difference between revisions of "Team:Evry/Project/SurfaceDisplay"

Line 42: Line 42:
 
<p class="text-justify">To establish a proof of concept, our system was tested in vivo on C57BL/6 mice injected with the melanoma cell line B16-OVA expressing the ovalbumin antigen. We also tested the system in vitro on hybridoma B3Z T-cells specific for SIINFEKL. The tumor antigen cloned in our vector was OVA1 corresponding to the sequence QLESIINFEKLTEW, class I (Kb)-restricted peptide epitope of ovalbumin (OVA) plus 3 amino acids around the epitope to allow better digestion by the proteasome. It is presented by the class I MHC molecule H-2Kb (29).</p>
 
<p class="text-justify">To establish a proof of concept, our system was tested in vivo on C57BL/6 mice injected with the melanoma cell line B16-OVA expressing the ovalbumin antigen. We also tested the system in vitro on hybridoma B3Z T-cells specific for SIINFEKL. The tumor antigen cloned in our vector was OVA1 corresponding to the sequence QLESIINFEKLTEW, class I (Kb)-restricted peptide epitope of ovalbumin (OVA) plus 3 amino acids around the epitope to allow better digestion by the proteasome. It is presented by the class I MHC molecule H-2Kb (29).</p>
  
<img src="https://static.igem.org/mediawiki/2015/a/ab/Sch%C3%A9ma.jpg" usemap="#imgmap2015916171923" id='image-map-py' width="500"/>
+
<div class="row">
 
+
<div class="col-md-4"><img border="0" src="https://static.igem.org/mediawiki/2015/a/ab/Sch%C3%A9ma.jpg" alt="" /></div>
 
+
<div class="col-md-8">
 
+
<p class="text-justify"> (1) Surface Display of tumor antigen OVA1 fused to DEC205 scFv. 
 
+
    (2) Yeast internalization in cross-presenting endosomes specific for DEC205
 +
    (3) CD8+ T cell cross-priming with tumor antigen OVA1
 +
  (4)  Cancer cell lysis with antigen OVA1 targetin </p>
 +
</div>
 +
</div>
 +
</div>
  
  

Revision as of 22:09, 18 September 2015

References

22. Howland SW, Wittrup KD, Antigen release kinetics in the phagosome are critical to cross-presentation efficiency. J Immunol 2008;180:1576–1583

23. Anjuere F, Martin P, Ferrero I, Fraga ML, del Hoyo GM, Wright N, Ardavin C, Definition of dendritic cell subpopulations present in the spleen, Peyer’s patches, lymph nodes, and skin of the mouse, 1999, Blood 93, 590–598

24. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii SI, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM, In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. 2004, J. Exp. Med. 199, 815–824

25. Demangel C, J Zhou, A BH Choo, G Shoebridge, GM. Halliday, WJ Britton, Single chain antibody fragments for the selective targeting of antigens to dendritic cells, 2005 May, Mol Immunol. 42(8):979-85

26. Petrovsky N, Aguilar JC, Vaccine adjuvants: current state and future trends Immunol Cell Biol. 2004;82:488–496

24. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii SI, Soares H, Brimnes MK, Moltedo B, Moran TM, Steinman RM, In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. 2004, J. Exp. Med. 199, 815–824.

25.Demangel C, J Zhou, A BH Choo, G Shoebridge, GM. Halliday, WJ Britton, Single chain antibody fragments for the selective targeting of antigens to dendritic cells, 2005 May, Mol Immunol. 42(8):979-85.

26. Petrovsky N, Aguilar JC, Vaccine adjuvants: current state and future trends Immunol Cell Biol. 2004;82:488–496.

27. Howland SW, T Tsuji, S Gnjatic, G Ritter, LJ. Old and K D Wittrup, Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles, J Immunother. 2008 September ; 31(7): 607. doi:10.1097/CJI.0b013e318181c87f.

28. Pan Y, Li X, Kang T, Meng H, Chen Z, Yang L, Wu Y, Wei Y, Gou M, Efficient delivery of antigen to DCs using yeast-derived microparticles, 2015, Sci. Rep. 5, 10687; doi: 10.1038/srep10687.

29. Rötzschke O, Falk K, Stevanović S, Jung G, Walden P, Rammensee HG, Exact prediction of a natural T cell epitope, 1991, Eur J Immunol.21(11):2891-4.

30. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony–stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543.

31. Hun K, R Hayashi, A Lafond-Walker, C Lowenstein, D Pardoll, H Levitsky, The central role of CD4+ T cells in the antitumor immune response, 1998, J. Exp. Med. 188, pp. 2357–2368.

32. Bookman MA, Swerdlow R, Matis LA: Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol 1987, 139:3166-3170.

33. Johnsen G & Elsayed S, Antigenic and allergenic determinants of ovalbumin-111. MHC Ia-binding peptide (OA 323-339) interacts with human and rabbit specific antibodies, 1990, Mol Immunol. 27821-7.

Scroll to top To top